Skip navigation

DSpace

機構典藏 DSpace 系統致力於保存各式數位資料(如:文字、圖片、PDF)並使其易於取用。

點此認識 DSpace
DSpace logo
English
中文
  • 瀏覽論文
    • 校院系所
    • 出版年
    • 作者
    • 標題
    • 關鍵字
    • 指導教授
  • 搜尋 TDR
  • 授權 Q&A
    • 我的頁面
    • 接受 E-mail 通知
    • 編輯個人資料
  1. NTU Theses and Dissertations Repository
  2. 管理學院
  3. 會計與管理決策組
請用此 Handle URI 來引用此文件: http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/70098
完整後設資料紀錄
DC 欄位值語言
dc.contributor.advisor吳琮璠(Chung-Fern Wu)
dc.contributor.authorJin-Shuen Chenen
dc.contributor.author陳金順zh_TW
dc.date.accessioned2021-06-17T03:43:22Z-
dc.date.available2019-03-01
dc.date.copyright2018-03-01
dc.date.issued2018
dc.date.submitted2018-02-05
dc.identifier.citation中文文獻
期刊
1.王茂源、何正得,作業基礎成本制度在訂價決策中的運用─以鋼鐵業Y公司為例,工程科技與教育學刊,第7卷第5期,2010年,頁745-761。
2.吳琮璠、劉順仁、陳引瑞,表達失真費率失準頭 安全準備計提不安全-全民健康保險財務表達問題之探討,會計研究月刊 ,159期,1999年02月,頁49-55。
3.何怡德,薛如婷,尿酸-代謝症候群預測指標,家庭醫學與基層醫療。30卷1期。2015年,頁9-14。
4.李玉春,健康保險與總額支付制度,收錄於楊志良主編,健康保險,2001年,頁71-117。
5.李政益、江亭誼、羅秀雲、莊人祥、吳怡君、楊祥麟,台灣健保論質計酬支付制度之發展-以結核病為例,疫情報導,第28卷 第19期,2012年,頁311-322。
6.李降生,全民健保改制--HMOs是答案嗎?,醫院,31期6卷,1998年,頁33-40。
7.林恆慶、陳楚杰,管理式醫療對醫師的影響 ─ 美國經驗,醫學教育,7卷3期,2003年,頁4-11。
8.林恆慶、黃子芬、李照軒,管理式醫療介紹,台灣衛誌,第20期第5卷,2001年,頁331-336。
9.高齡化對醫療費用的衝擊及因應之道,全民健康保險雙月刊第104期,102年7月號。
10.郭倉義、張瑞當、沈文華、林文豪,作業基礎成本管理制度效能之分析:以一貫作業鋼廠為例,中華管理評論國際學報,第11卷3期,2008 年8 月,頁1-31。
11.錢慶文,「作業制成本會計制度在醫院成本會計上之應用」,醫院雜誌,第27卷第3期,1994年,頁1-7。
12.蔡世澤,台灣糖尿病照護現況與省思。臨床醫學,第45卷5期,2000年,頁316-320。
13.謝冠賢,作業制成本制應用於醫院成本分攤之見解。醫院1993;第26卷第1期,1993年,頁40-44。
碩博士論文
1.許芳瑾,痛風患者的醫療利用分析,中國醫藥學院醫務管理研究所碩士論文,2003年。
專書
1.朱宗信、陳金順,第三章醫學知識,住院醫師教育的六大核心能力,第2 版,臺北市,九州。
2.李玉君、吳明孝、張道義、蔡茂寅,社會法,第十一章全民健康保險(修訂二版),台灣社會法與社會政策學會主編,元照,頁278-286。
3.馬嘉應,張力。會計學導論(4版),台灣五南圖書出版股份有限公司,2012年。
4.楊志良主持,行政院研究發展考核委員會編,全民健康保險有關醫療行為規制問題探討, 1993年。
5.羅紀琼,健康保險制度-日、德、法、荷的經驗與啟示,台北,巨流圖書,2006年。

其他
1.2015臺灣慢性腎臟病臨床診療指引,財團法人國家衛生研究院發行。
2.台灣痛風與高尿酸血症2017診治指引,中華民國風濕病醫學會。
3.全民健保20年 造就臺灣瑰寶,全民健康保險雙月刊第114期 (104年3月號) 。
4.全民健康保險制度規劃報告第六章保險財務,行政院經建會全民健康保險規劃小組研究計畫專案小組,民國79年06月。
5.金色挑戰:全民健保納保及財務平衡施政紀實,衛生福利部中央健康保險署出版,2014年。
6.吳琮璠、劉順仁,全民健康保險財務監理與稽核作業研究,1998年,全民健保監理委員會委託研究DOH87- HS-1002。
7.高齡友善城市 全臺總動員,衛生福利部、國民健康署發行。
8.新北市藥師工會,治療頑固型痛風的新選擇Pegloticase。http://tcpa.taiwan-pharma.org.tw/node/13309
9.衛生福利部中央健保署,白色守護:全民健保醫療支付與管理施政紀實,衛生福利部中央健康保險署,2014年。
10.劉順仁,經理人月刊,56期名師一堂課,劉順仁管理會計之成本分析。https://www.managertoday.com.tw/glossary/view/54

英文文獻
Journal
1.Annemans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, Gilbert T, Nuki G. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis. 2008 Jul;67(7):960-6.
2.Akhavan S, Ward L, Bozic KJ. Time-driven Activity-based Costing More Accurately Reflects Costs in Arthroplasty Surgery. Clin Orthop Relat Res. 2016 Jan;474(1):8-15.
3.Babio N, Martínez-González MA, Estruch R, Wärnberg J, Recondo J, Ortega-Calvo M, Serra-Majem L, Corella D, Fitó M, Ros E, Becerra-Tomás N, Basora J, Salas-Salvadó J. Associations between serum uric acid concentrations and metabolic syndrome and its components in the PREDIMED study. Nutr Metab Cardiovasc Dis. 2015 Feb;25(2):173-80.
4.Bagby SP. Obesity-initiated metabolic syndrome and the kidney: A recipe for chronic kidney disease? J Am Soc Nephrol 15:2775-2791, 2004.
5.Bauer-Nilsen K, Hill C, Trifiletti DM, Libby B, Lash DH, Lain M, Christodoulou D, Hodge C, Showalter TN. Evaluation of Delivery Costs for External Beam Radiation Therapy and Brachytherapy for Locally Advanced Cervical Cancer Using Time-Driven Activity-Based Costing. Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):88-94.
6.Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med. 1987 Mar;82(3):421-6.
7.Chao TF, Liu CJ, Chen SJ, Wang KL, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chen TJ, Tsao HM, Chen SA. Hyperuricemia and the risk of ischemic stroke in patients with atrial fibrillation--could it refine clinical risk stratification in AF? Int J Cardiol. 2014 Jan 1;170(3):344-9.
8.Chen J, Muntner P, Hamm LL et al. The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med 140:167-174, 2004.
9.Chuang SY, Chen JH, Yeh WT, Wu CC, Pan WH. Hyperuricemia and increased risk of ischemic heart disease in a large Chinese cohort. Int J Cardiol. 2012;154(3):316–21.
10.Chuang SY, Lee SC, Hsieh YT, Pan WH. Trends in hyperuricemia and gout prevalence: Nutrition and Health Survey in Taiwan from 1993-1996 to 2005-2008. Asia Pac J Clin Nutr. 2011;20(2):301-8.
11.Civan A, Köksal B. The effect of newer drugs on health spending: do they really increase the costs? Health Econ. 2010 May;19(5):581-95.
12.Culleton BF, Larson MG, Kannel WB, et al. Serum uric acid and risk for cardiovascular disease and death: The Framingham Heart Study. Ann Intern Med 1999;131:7-13.
13.Culleton BF, Larson MG, Kannel WB, Levy D.Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med. 1999 Jul 6;131(1):7-13.
14.Daskalopoulou SS, Tzovaras V, Mikhailidis DP, Elisaf M. Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia. Curr Pharm Des. 2005;11(32):4161-75.
15.Dave D, Kaestner R. Health insurance and ex ante moral hazard: evidence from Medicare. Int J Health Care Finance Econ. 2009 Dec;9(4):367-90.
16.de Preux LB. Anticipatory ex ante moral hazard and the effect of Medicare on prevention. Health Econ. 2011 Sep;20(9):1056-72.
17.Dincer HE, Dincer AP, Levinson DJ. Asymptomatic hyperuricemia: to treat or not to treat. Cleve Clin J Med. 2002 Aug;69(8):594, 597, 600-2 passim.
18.Dylewski JS, Gerson M. Hyperuricemia in patients with infectious mononucleosis. Can Med Assoc J. 1985 May 15;132(10):1169-70.
19.Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA. 2000 May 10;283(18):2404-10.
20.Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008 Oct 23;359(17):1811-21.
21.Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the Third National Health and Nutrition Examination Survey. JAMA , 2002, 287:356-9.
22.Goicoechea M, Garcia de Vinuesa S, Verdalles U, Verde E, Macias N, Santos A, Pérez de Jose A, Cedeño S, Linares T, Luño J. Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial. Am J Kidney Dis. 2015 Apr;65(4):543-9.
23.Greenwood T. G. and Reeve I. M.,“Activity-based cost management for continuous improvement : A process design frame,”Journal of Cost Management, 1992, Vol.5, pp.22-40.
24.Handelsman Y, Bloomgarden ZT, Grunberger G, Umpierrez G, Zimmerman RS, Bailey TS, Blonde L, Bray G, Cohen A, Dagogo-Jack S, Davidson JA, Einhorn D, Ganda OP, Garber AJ, Garvey WT, Henry RR, Hirsch IB, Horton ES, Hurley DL, Jellinger PS, Jovanovič L, Lebovitz HE, LeRoith D, Levy P, McGill JB, Mechanick JI, Mestman JH, Moghissi ES, Orzeck EA, Pessah-Pollack R, Rosenblit PD, Vinik AI, Wyne K, Zangeneh F. American association of clinical endocrinologists and american college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. Endocr Pract. 2015 Apr;21 Suppl 1:1-87.
25.Hanley AJ, Wagenknecht LE, D’Agostino RB Jr, Zinman B, Haffner SM. Identification of subjects with insulin resistance and beta-cell dysfunction using alternative definitions of the metabolic syndrome. Diabetes 52:2740-2747, 2003.
26.Igel TF, Krasnokutsky S, Pillinger MH Recent advances in understanding and managing gout. F1000Res. 2017 Mar 10;6:247.
27.Iliesiu A, Campeanu A, Dusceac D.Serum uric acid and cardiovascular disease. Maedica (Buchar). 2010 Jul;5(3):186-92.
28.Jang SI, Nam CM, Lee SG, Kim TH, Park S, Park EC. Impact of payment system change from per-case to per-diem on high severity patient's length of stay. Medicine (Baltimore). 2016 Sep;95(37):e4839
29.Javid M, Hadian M, Ghaderi H, Ghaffari S, Salehi M. Application of the Activity-Based Costing Method for Unit-Cost Calculation in a Hospital. Glob J Health Sci. 2015 May 17;8(1):165-72.
30.Jegers M, Kesteloot K, De Graeve D, Gilles W. A typology for provider payment systems in health care. Health Policy. 2002 Jun;60(3):255-73.
31.Kanji T, Gandhi M, Clase CM, Yang R. Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol. 2015 Apr 19;16:58.
32.Kaplan RS, Anderson SR. The innovation of time-driven activitybased costing. Journal of Cost Management. 2007;21(2): 5–15.
33.Keel G, Savage C, Rafiq M, Mazzocato P. Time-driven activity-based costing in health care: A systematic review of the literature. Health Policy. 2017 Jul;121(7):755-763.
34.Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Lioté F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, Roessler B, Kerr G, King C, Levy G, Furst DE, Edwards NL, Mandell B, Schumacher HR, Robbins M, Wenger N, Terkeltaub R; American College of Rheumatology. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012 Oct;64(10):1431-46.
35.Kiani, R., & Sangeladji, M. An empirical study about the use of ABC/ABM models by some of the fortune 500 largest industrial corporations in the USA. Journal of American. Academy of Business. 2003, 3(1/2): 174-182.
36.Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA: Metabolic syndrome and development of diabetes mellitus: Application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 156:1070-1077, 2002.
37.Lai LH, Chou SY, Wu FY, Chen JJ, Kuo HW. Renal dysfunction and hyperuricemia with low blood lead levels and ethnicity in community-based study. Sci Total Environ. 2008 Aug 15;401(1-3):39-43.
38.Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288:2709-2716, 2002.
39.Li Y, Stamler J, Xiao Z, Folsom A, Tao S, Zhang H. Serum uric acid and its correlates in Chinese adult populations, urban and rural, of Beijing. The PRC-USA Collaborative Study in Cardiovascular and Cardiopulmonary Epidemiology. Int J Epidemiol. 1997 Apr;26(2):288-96.
40.Liang CC, Lin PC, Lee MY, Chen SC, Shin SJ, Hsiao PJ, Lin KD, Hsu WH. Association of Serum Uric Acid Concentration with Diabetic Retinopathy and Albuminuria in Taiwanese Patients with Type 2 Diabetes Mellitus. Int J Mol Sci. 2016 Aug 2;17(8).
41.Lin KC, Lin HY, Chou P. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol. 2000 Jun;27(6):1501-5.
42.Liu P, Chen Y, Wang B, Zhang F, Wang D, Wang Y. Allopurinol treatment improves renal function in patients with type 2 diabetes and asymptomatic hyperuricemia: 3-year randomized parallel-controlled study. Clin Endocrinol (Oxf). 2015 Oct;83(4):475-82.
43.Liu WC, Hung CC, Chen SC, Yeh SM, Lin MY, Chiu YW, Kuo MC, Chang JM, Hwang SJ, Chen HC. Association of hyperuricemia with renal outcomes, cardiovascular disease, and mortality. Clin J Am Soc Nephrol. 2012 Apr;7(4):541-8.
44.Lytvyn Y, Perkins BA, Cherney DZ. Uric acid as a biomarker and a therapeutic target in diabetes. Can J Diabetes. 2015 Jun;39(3):239-46.
45.Matthew E. Pollard, Aaron A. Laviana, Alan L. Kaplan, Casey Pagan, Christopher S. Saigal. Time-Driven Activity-Based Costing Analysis of Urologic Stone Disease. Urology Practice Available online 28 September 2017. https://www.sciencedirect.com/science/article/pii/S2352077917302194
46.Me-cimore, C. D. and A. T. Bell, 'Are We Ready for Fourth-Generation ABC?. Management Accounting, Vol. 76, No. 1, 1995, pp. 22-26.
47.Mihailovic N, Kocic S, Jakovljevic M.Review of Diagnosis-Related Group-Based Financing of Hospital Care. Health Serv Res Manag Epidemiol. Health. 2016 May 12;3:2333392816647892.
48.National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106:3143-3421, 2002.
49.Ninomiya JK, L’Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS. Association of the metabolic syndrome with history of myocardial infarction and stroke in the third national health and nutrition examination survey. Circulation 109:42-46, 2004.
50.Perez-Ruiz F, Dalbeth N, Bardin T. A review of uric acid, crystal deposition disease, and gout. Adv Ther. 2015 Jan;32(1):31-41.
51.Prasad Sah OS, Qing YX. Associations Between Hyperuricemia and Chronic Kidney Disease: A Review. Nephrourol Mon. 2015 May 23;7(3):e27233.
52.Rai SK, Burns LC, De Vera MA, Haji A, Giustini D, Choi HK. The economic burden of gout: A systematic review. Semin Arthritis Rheum. 2015 Aug;45(1):75-80.
53.Rai SK, Burns LC, De Vera MA, Haji A, Giustini D, Choi HK. The economic burden of gout: A systematic review. Semin Arthritis Rheum. 2015 Aug;45(1):75-80.
54.Rathmann W, Funkhouser E, Dyer AR, et al. Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the Cardia study. Coronary Artery Risk Development in Young Adults. Ann Epidemiol 1998; 8:250-61.
55.Reaven GM. Role of insulin resistance in human disease. Diabetes. 37:1595-1607, 1988.
56.Richette P, Perez-Ruiz F, Doherty M, Jansen TL, Nuki G, Pascual E, Punzi L, So AK, Bardin T. Improving cardiovascular and renal outcomes in gout: what should we target? Nat Rev Rheumatol. 2014 Nov;10(11):654-61.
57.Roughley MJ, Belcher J, Mallen CD, Roddy E. Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies. Arthritis Res Ther. 2015 Apr 1;17:90.
58.Sautin YY, Johnson RJ. Uric acid: the oxidant-antioxidant paradox. Nucleosides Nucleotides Nucleic Acids. 2008 Jun;27(6):608-19.
59.Shadick NA, Kim R, Weiss S, Liang MH, Sparrow D, Hu H. Effect of low level lead exposure on hyperuricemia and gout among middle aged and elderly men: the normative aging study. J Rheumatol. 2000 Jul;27(7):1708-12.
60.Sharaf El Din UAA, Salem MM, Abdulazim DO. Uric acid in the pathogenesis of metabolic, renal, and cardiovascular diseases: A review. J Adv Res. 2017 Sep;8(5):537-548.
61.Shields GE, Beard SM. A Systematic Review of the Economic and Humanistic Burden of Gout. Pharmacoeconomics. 2015 Oct;33(10):1029-47.
62.Sircar D, Chatterjee S, Waikhom R, Golay V, Raychaudhury A, Chatterjee S, Pandey R. Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial. Am J Kidney Dis. 2015 Dec;66(6):945-50.
63.Sircar D, Chatterjee S, Waikhom R, Golay V, Raychaudhury A, Chatterjee S, Pandey R. Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial. Am J Kidney Dis. 2015 Dec;66(6):945-50. doi: 10.1053/j.ajkd.2015.05.017.
64.Spaetgens B, Boonen A. The importance of 'state-of-the-art' cost-of-illness studies. Comment on: The economic burden of gout: A systematic review. Semin Arthritis Rheum. 2016 Feb;45(4):e9.
65.Spaetgens B, de Vries F, Driessen JHM, Leufkens HG, Souverein PC, Boonen A, van der Meer JWM, Joosten LAB. Risk of infections in patients with gout: a population-based cohort study. Sci Rep. 2017 May 3;7(1):1429.
66.Stewart S, Dalbeth N, Vandal AC, Rome K. The first metatarsophalangeal joint in gout: a systematic review and meta-analysis. BMC Musculoskelet Disord. 2016 Feb 11;17:69.
67.Stewart S, Dalbeth N, Vandal AC, Rome K. The first metatarsophalangeal joint in gout: a systematic review and meta-analysis. BMC Musculoskelet Disord. 2016 Feb 11;17:69.
68.Tian Y, Chen K, Xie Z, Fang Y, Wang H, Nie Y, Hu D, Mu Y. The association between serum uric acid levels, metabolic syndrome and cardiovascular disease in middle aged and elderly Chinese: results from the DYSlipidemia International Study. BMC Cardiovasc Disord. 2015 Jul 11;15:66.
69.Tsouli SG, Liberopoulos EN, Mikhailidis DP, Athyros VG, Elisaf MS. Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism. 2006 Oct;55(10):1293-301.
70.Udpa S. Activity-based costing for hospitals. Health Care Manage Rev. 1996 Summer;21(3):83-96.
71.Wei CY, Sun CC, Wei JC, Tai HC, Sun CA, Chung CF, Chou YC, Lin PL, Yang T. Association between Hyperuricemia and Metabolic Syndrome: An Epidemiological Study of a Labor Force Population in Taiwan. Biomed Res Int. 2015;2015:369179.
72.Wortmann, R.L. and Kelley, W.N., Gout and hyperuricemia., H.E. Kelley WN, Ruddy S, Sledge CB, Editor. 2005, W.B. Saunders: Philadelphia. p. 1402-48.
73.Yang CY, Chen CH, Deng ST, Huang CS, Lin YJ, Chen YJ, Wu CY, Hung SI, Chung WH. Allopurinol Use and Risk of Fatal Hypersensitivity Reactions: A Nationwide Population-Based Study in Taiwan. JAMA Intern Med. 2015 Sep;175(9):1550-7.
74.Yu KH, Yu CY, Fang YF. Diagnostic utility of HLA-B*5801 screening in severe allopurinol hypersensitivity syndrome: an updated systematic review and meta-analysis. Int J Rheum Dis. 2017 Aug 31.
75.Zalawadiya SK, Veeranna V, Mallikethi-Reddy S, Bavishi C, Lunagaria A, Kottam A, Afonso L. Uric acid and cardiovascular disease risk reclassification: findings from NHANES III. Eur J Prev Cardiol. 2015 Apr;22(4):513-8.
76.Zweifel P, Breuer M. The case for risk-based premiums in public health insurance. Health Econ Policy Law. 2006 Apr;1(Pt 2):171-88.
Book
1.Disorders of Purine and Pyrimidine Metabolism, Harrison's Principles of Internal Medicine, 19e; 2015. Available at: https://accessmedicine.mhmedical.com/ViewLarge.aspx?figid=98733903&gbosContainerID=0&gbosid=0 Accessed: August 24, 2017
2.Harrison's Principles of Internal Medicine, 19e. Part 16: Endocrinology and Metabolism, Section 5: Disorders of Intermediary Metabolism, 431e: Disorders of Purine and Pyrimidine Metabolism. Christopher M. Burns; Robert L. Wortmann.
3.Kaplan, Robert S., and Robin Cooper. Cost and Effect: Using Integrated Cost Systems to Drive Profitability and Performance. Boston: Harvard Business School Press, 1998. At p99-107.
4.Richard J. Johnson,Timothy Gower. The Sugar Fix: The high-fructose fallout that is making you fat and sick. Mass Market Paperback, 2009.
5.Robbins DA: Managed care on trial: recapturing trust, integrity, and accountability in healthcare. McGraw-Hill, New York, NY 1998:3-4, 1998.

Other
1.2016 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States. Volume 2: ESRD in the United States. Chapter 13 • International Comparisons. https://www.usrds.org/adr.aspx
2.A systematic review of the cost burden of gout. Presented at the ISPOR 18thAnnual European Congress, 7–11 November 2015, Milan, Italy. https://www.google.com.tw/url?sa=t&rct=j&q=&esrc=s&source=web&cd=6&cad=rja&uact=8&ved=0ahUKEwi39oTtp-PYAhWIwLwKHUNaAxIQFghSMAU&url=https%3A%2F%2Fwww.ispor.org%2Fresearch_pdfs%2F51%2Fpdffiles%2FPMS126.pdf&usg=AOvVaw1qN6FFo9WxZ3frp9O86wDi
3.Global Report on Diabetes. World Health Organization. 2016 at pp4,6. http://apps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdf

網站資源
1.衛生福利部,統計處http://dep.mohw.gov.tw/DOS/np-1714-113.html
2.衛生福利部https://www.mohw.gov.tw/mp-1.html
3.衛生福利部中央健保署網站,資訊公開https://www.nhi.gov.tw/Content_List.aspx?n=CDA985A80C0DE710&topn=CDA985A80C0DE710
4.衛生福利部中央健保署網站https://www.nhi.gov.tw/
5.衛生福利部最新消息http://www.mohw.gov.tw/cp-16-33598-1.html
6.http://ndltd.ncl.edu.tw/cgi-bin/gs32/gsweb.cgi/ccd=PLJyw4/search#result
7.http://ndltd.ncl.edu.tw/cgi-bin/gs32/gsweb.cgi/ccd=PLJyw4/search#result
8.http://ndltd.ncl.edu.tw/cgi-bin/gs32/gsweb.cgi/ccd=PLJyw4/search#result
9.http://ndltd.ncl.edu.tw/cgi-bin/gs32/gsweb.cgi/ccd=PLJyw4/search#result
10.http://www.genetinfo.com/investment/featured/item/4119.html
11.http://www.learnaccounting.tw/mgt-acc-ch1q.html
12.https://kknews.cc/zh-tw/health/aoe436j.html
13.https://kknews.cc/zh-tw/health/z6l4xn3.html
14.https://ndltd.ncl.edu.tw/cgi-bin/gs32/gsweb.cgi/ccd=o86iDX/search#result
15.https://ndltd.ncl.edu.tw/cgi-bin/gs32/gsweb.cgi/ccd=o86iDX/search#result
16.https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=1131&pid=2276
17.https://www.ncbi.nlm.nih.gov/pubmed/?term=Uric+acid+%2B+Gout+%2B+accident
18.https://www.ncbi.nlm.nih.gov/pubmed/?term=Uric+acid+%2B+Gout+%2B+Cardiovascular+%2For+Stroke
19.https://www.ncbi.nlm.nih.gov/pubmed/?term=Uric+acid+%2B+Gout+%2B+CKD+%2For+renal+function
20.https://www.ncbi.nlm.nih.gov/pubmed/?term=Uric+acid+%2B+Gout+%2B+DM+or+blood+sugar
21.https://www.ncbi.nlm.nih.gov/pubmed/?term=uric+acid+gout+metabolic+syndrome
22.https://www.ncbi.nlm.nih.gov/pubmed/?term=uric+acid+gout+metabolic+syndrome
23.https://www.uptodate.com/contents/uric-acid-balance
dc.identifier.urihttp://tdr.lib.ntu.edu.tw/jspui/handle/123456789/70098-
dc.description.abstract台灣健保醫療費用逐年增加,但健保保費收入年成長率低於醫療支出年成長率,導致現行健保制度財務危機逐日惡化;如何維持良好的醫療品質,並兼顧醫療成本的控制及醫療資源的合理分配,已成為健康管理層面重要的課題;如何透過有效的病案及疾病管理,來有效率並公平的分配有限的醫療資源是值得探討的議題。
首先本論文提出一管理會計之疾病管理模式平台,相關步驟為「第一步:找出可治癒之單一疾病」、「第二步:確認此單一疾病與其他慢性病之醫療關係」、「第三步:確認此單一疾病與其他主要急、慢性病之財務(醫療成本耗用)之關係」、「第四步:介入性研究或政策制訂」、「第五步:成果及回饋」,以文獻搜尋分析及統計分析方法之研究方法為主,探討「高尿酸血症與慢性疾病」及「高尿酸血症與急性病」健保醫療成本耗費之關係。主要之結果為,首先在第一步中,找出尿酸是可被治癒的疾病,在慢性疾病部分,主要是代謝症候群、糖尿病、心血管疾病,及腎臟疾病;在急性疾病部分,主要是急性感染及意外事故;在第二步中,藉由國內外文獻搜尋,證實尿酸是與各類急、慢性病之發生、惡化具有意義因果關係;在第三步中,本論文透過文獻搜尋、台灣健保資料庫及百萬歸人檔統計分析,證實台灣尿酸疾病費用之支出與其他急、慢性病具有意義之正相關性,更進一步證實高尿酸與意外事故之產生具有意義之正相關性;在第四步中,本文建議尿酸應納入臨床成人常規性健康檢查項目,並及早治癒高尿酸血症,針對高尿酸血症之患者加強交通安全、意外事故預防之教育;在第五步中,提供學界、醫界及政府單位以本論文所提之管理會計之疾病管理模式平台,尋找其他可控制且可治癒之單一疾病,做有效疾病管理
藉由本論文之結果及討論,我們認為透過成本會計之分析配合臨床疾病之病生理因果關係,是可以有效提升醫療品質、促進健康,同時更妥善控制醫療財務成本。
zh_TW
dc.description.abstractTaiwan’s National Health Insurance (NIH) expenses are increasing yearly, but the annual growth rate of the premium income is lower than that of medical expenditure. As a result, the NIH is unable to balance its expenses. How to maintain good medical quality, control medical costs and allocate limited medical resources efficiently: These are important issues for health administration in Taiwan. This study use the platform of disease management to achieve these aims.
In this study, a unique platform combining accounting management with disease management was created. Our first step was to find a disease that could be cured; the second step was to establish the causal relationship among the target disease, acute diseases, and chronic diseases; the third step was to confirm the financial (medical expenditure) relationship among the target disease, acute diseases and chronic diseases; the fourth step was to propose interventional study and develop administrative policy; and the final fifth step was to solicit feedback and refine the platform. The main results in the study are as follows, step by step: Hyperuricemia was chosen as the curable disease; the chronic diseases were metabolic diseases, diabetic mellitus, cardiovascular diseases and chronic kidney disease; and the acute diseases were acute infectious diseases and accident injuries. For the second step, according to the results of literature review, a positive causal correlation between hyperuricemia and development and deterioration of acute and chronic diseases was established. For the third step, according to the results of literature review and analysis of the Normalized Million People File, National Health Insurance Research Database, a positive correlation was established between the financial relationship for medical expenditure for hyperuricemia and that for acute and chronic diseases; and a positive relationship between hyperuricemia and the occurrence of accidental injury was also established. For the fourth step, we suggested that serum uric acid should be included as an essential item of adult systemic examination in Taiwan, and hyperuricemia should be treated and cured early. Furthermore, subjects with hyperuricemia should receive more education regarding traffic safety and accident prevention. For the fifth step, we suggest that researchers look for other curable single diseases for which they can use our study platform to achieve efficient disease management.
In conclusion, based on the integration of analysis of medical costs and analysis of causal relationship of diseases, we can achieve our aims of high-quality medical service, health improvements, and reasonable allocation of medical resources.
en
dc.description.provenanceMade available in DSpace on 2021-06-17T03:43:22Z (GMT). No. of bitstreams: 1
ntu-107-P04744022-1.pdf: 3217543 bytes, checksum: 8992ef3ec77872b48485c5de8eca29f7 (MD5)
Previous issue date: 2018
en
dc.description.tableofcontents中文摘要 ………………………………………………………I
Abstract.………………………………………………………II
目錄……………………………………………………………I
表目錄…………………………………………………………V
圖目錄………………………………………………………IV
第1章緒論……………………………………………………1
1.1.研究動機…………………………………………………1
1.2.研究問題…………………………………………………2
1.3.研究目的…………………………………………………2
1.4.研究設計與方法…………………………………………3
1.4.1.研究設計與架構…………………………………………3
1.4.1.1.管理會計之疾病管理平台……………………………3
1.4.1.2.尿酸之管理會計之疾病管理平台……………………4
1.4.2.研究方法…………………………………………………5
1.4.3.論文架構…………………………………………………6
第2章研究背景………………………………………………8
2.1.疾病管理…………………………………………………8
2.2.健保與會計………………………………………………10
2.2.1.台灣健保制度…………………………………………12
2.2.2.台灣健保制度與會計…………………………………13
2.2.2.1.管理會計(managerial accounting)………………14
2.2.2.2.管理會計之成本分析………………………………15
2.2.3.台灣健保管理會計之財務規劃………………………19
2.2.2.3.台灣健保財務特性…………………………………19
2.2.2.4.台灣健保保費收入制度……………………………22
2.2.2.5.台灣健保疾病管理支付制度………………………24
2.3.尿酸與疾病管理…………………………………………31
2.3.1.尿酸之基本人體代謝狀況及生理角色………………31
2.3.2.高尿酸之危害…………………………………………34
2.3.2.1.台灣高尿酸定義……………………………………34
2.3.2.2.高尿酸的原因………………………………………34
2.3.2.3.高尿酸對人體的危害………………………………38
2.3.2.4.高尿酸與痛風(Gout)……………………………39
2.3.3.高尿酸之疾病管理……………………………………40
2.4.目前挑戰…………………………………………………45
第3章研究方法……………………………………………47
3.1.研究設計…………………………………………………47
3.1.1.管理會計之疾病管理平台……………………………47
3.1.2.尿酸之管理會計之疾病管理平台……………………48
3.1.2.1.尿酸與慢性病研究流程……………………………49
3.1.2.2.尿酸與急性病研究流程……………………………50
3.2.文獻搜尋…………………………………………………50
3.2.1.研究方法………………………………………………50
3.3.健保資料…………………………………………………51
3.3.1.研究方法………………………………………………51
3.3.2.資料來源………………………………………………52
3.3.3.研究對象………………………………………………52
3.3.4.變項定義………………………………………………53
3.3.5.台灣人口數……………………………………………53
3.3.6.健保醫療費用…………………………………………54
3.4.統計分析…………………………………………………54
第4章結果與分析…………………………………………56
4.1.尿酸與各類慢性病之關係………………………………56
4.1.1.醫療面…………………………………………………56
4.1.1.1.代謝症候群(Metabolic syndrome)………………56
4.1.1.2.糖尿病(Diabetic mellitus)…………………………58
4.1.1.3.心血管疾病(Cardiovascular disease)……………60
4.1.1.4.腎臟疾病(Kidney Disease)………………………62
4.1.2.會計面…………………………………………………64
4.1.2.1.文獻搜尋……………………………………………64
4.1.2.2.健保資料庫分析……………………………………65
4.2.尿酸與急性病症產生之關係……………………………67
4.2.1.醫療面…………………………………………………67
4.2.1.1.急性感染(Acute infections)………………………67
4.2.1.2.意外事故(Accident)………………………………68
4.2.2.會計面…………………………………………………68
4.2.2.1.意外事故健保分析…………………………………69
第5章討論…………………………………………………88
5.1.高尿酸血症之疾病管理…………………………………88
5.1.1.尿酸與各種慢性病……………………………………90
5.1.2.尿酸與急性病症………………………………………92
5.1.3.小結……………………………………………………93
5.2.管理會計之疾病管理模式………………………………94
5.2.1.管理會計成本分析與疾病管理………………………94
5.2.2.管理會計成本分析與疾病管理模式…………………96
第6章結論及建議…………………………………………100
第7章研究限制及未來方向………………………………101
7.1.研究限制………………………………………………101
7.2.未來方向………………………………………………101
參考資料……………………………………………………102
dc.language.isozh-TW
dc.subject疾病管理zh_TW
dc.subject醫療成本zh_TW
dc.subject管理會計zh_TW
dc.subject尿酸zh_TW
dc.subject意外事故zh_TW
dc.subjecthyperuricemiaen
dc.subjectaccountingen
dc.subjectdisease managementen
dc.subjectmedical expenditureen
dc.subjectaccidental injuryen
dc.title高尿酸與各類急慢性疾病健保耗用關係探索性之研究zh_TW
dc.titleAn Exploratory Study of the Relationships Among Hyperuricemia with Acute and Chronic Diseases Health Insurance Expenseen
dc.typeThesis
dc.date.schoolyear106-1
dc.description.degree碩士
dc.contributor.oralexamcommittee劉順仁(Shuen-Zen Liu),吳青松(Ching-Sung Wu)
dc.subject.keyword疾病管理,醫療成本,管理會計,尿酸,意外事故,zh_TW
dc.subject.keywordmedical expenditure,accounting,disease management,hyperuricemia,accidental injury,en
dc.relation.page117
dc.identifier.doi10.6342/NTU201800296
dc.rights.note有償授權
dc.date.accepted2018-02-05
dc.contributor.author-college管理學院zh_TW
dc.contributor.author-dept會計與管理決策組zh_TW
顯示於系所單位:會計與管理決策組

文件中的檔案:
檔案 大小格式 
ntu-107-1.pdf
  未授權公開取用
3.14 MBAdobe PDF
顯示文件簡單紀錄


系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。

社群連結
聯絡資訊
10617臺北市大安區羅斯福路四段1號
No.1 Sec.4, Roosevelt Rd., Taipei, Taiwan, R.O.C. 106
Tel: (02)33662353
Email: ntuetds@ntu.edu.tw
意見箱
相關連結
館藏目錄
國內圖書館整合查詢 MetaCat
臺大學術典藏 NTU Scholars
臺大圖書館數位典藏館
本站聲明
© NTU Library All Rights Reserved